Department of Obstetrics, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
School of Nursing, Nanjing Medical University, Nanjing, Jiangsu, China.
J Immunol Res. 2022 Apr 28;2022:2373694. doi: 10.1155/2022/2373694. eCollection 2022.
Preeclampsia remains a high cause of incidence and death for mothers and fetuses in developing nations. Preeclampsia has numerous clinical and biochemical markers that have been tested, but they have failed to provide a conclusive diagnosis in the different phases of the disease's progression. Herein, our team intended to determine potential diagnostic biomarkers for preeclampsia and analyzed associations with immune cells. Two microarray data from mankind's preeclampsia and control specimens were acquired from GSE75010 and GSE44711 datasets. Differentially expressed genes (DEGs) were identified between77 normal samples and 80 preeclampsia samples. Candidate biomarkers were discovered using the least absolute shrinkage and selection operator (LASSO) and the support vector machine recursive feature elimination (SVM-RFE) analysis. The expressions and diagnostic values of genes in preeclampsia were further demonstrated in the GSE44711 dataset (8 control samples and 8 preeclampsia samples). The correlation of critical genes with the proportion of immune cells was analyzed. We identified 20 DEGs in preeclampsia. Diseases enriched by DEGs were mainly related to preeclampsia, gestational diabetes, ovarian disease, female reproductive system disease, and endocrine system disease. COL17A1, FLT1, FSTL3, and SERPINA3 were identified as diagnostic genes of preeclampsia and validated in the GSE44711 datasets. Immune cell infiltration assays suggested that COL17A1, FLT1, FSTL3, and SERPINA3 were related to several immune cells. Overall, we identified four critical diagnostic genes in preeclampsia. Furthermore, more well-designed research studies with larger cohorts were warranted to confirm the value of the four genes for the diagnosis and outcome of preeclampsia patients.
子痫前期仍然是发展中国家母亲和胎儿发病率和死亡率的一个主要原因。子痫前期有许多已被测试的临床和生化标志物,但它们未能在疾病进展的不同阶段提供明确的诊断。在此,我们的团队旨在确定子痫前期的潜在诊断生物标志物,并分析与免疫细胞的关联。从 GSE75010 和 GSE44711 数据集获得了人类子痫前期和对照标本的两个微阵列数据。在 77 个正常样本和 80 个子痫前期样本之间确定了差异表达基因(DEGs)。使用最小绝对收缩和选择算子(LASSO)和支持向量机递归特征消除(SVM-RFE)分析发现候选生物标志物。在 GSE44711 数据集(8 个对照样本和 8 个子痫前期样本)中进一步证明了子痫前期中基因的表达和诊断价值。分析了关键基因与免疫细胞比例的相关性。我们在子痫前期中鉴定了 20 个 DEG。DEG 富集的疾病主要与子痫前期、妊娠糖尿病、卵巢疾病、女性生殖系统疾病和内分泌系统疾病有关。COL17A1、FLT1、FSTL3 和 SERPINA3 被鉴定为子痫前期的诊断基因,并在 GSE44711 数据集得到验证。免疫细胞浸润分析表明,COL17A1、FLT1、FSTL3 和 SERPINA3 与几种免疫细胞有关。总的来说,我们在子痫前期中鉴定了四个关键的诊断基因。此外,需要进行更多设计良好的研究,以更大的队列来验证这四个基因在子痫前期患者的诊断和预后中的价值。